Does switching the bacillus Calmette-Gu érin strain affect clinical outcome in patients with recurrent non–muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?

It is still unknown whether switching the bacillus Calmette-Gu érin (BCG) strain at the second induction course of BCG therapy has a therapeutic benefit in patients with tumor recurrence after the initial BCG therapy (BCG-relapsing tumor).

Source: Urologic Oncology: Seminars and Original Investigations - March 9, 2018 Category: Urology & Nephrology Authors: Naoya Niwa, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya Tags: Original article Source Type: research